Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Pancreatic cancer

Epidermal growth factor receptor (EGFR); HER2 (EGFR2; ErbB2; neu)

Mouse studies identified combinations of antibodies targeting HER2 and EGFR that could help treat pancreatic cancer. In mice with human pancreatic ductal adenocarcinoma xenografts, intraperitoneal injection of mAbs targeting HER2 or EGFR had a small effect on tumor growth, whereas combinations of the antibodies synergistically inhibited tumor growth and increased the fraction of tumor-free mice. Next steps include humanizing the relevant antibodies.

SciBX 6(38); doi:10.1038/scibx.2013.1063
Published online Oct. 3, 2013

Patent application filed; available for licensing

Maron, R. et al. Proc. Natl. Acad. Sci. USA; published online Sept. 3, 2013;
doi:10.1073/pnas.1313857110
Contact: Michael Sela, Weizmann Institute of Science, Rehovot, Israel
e-mail:
michael.sela@weizmann.ac.il

Contact: Yosef Yarden, same affiliation as above
e-mail:
yosef.yarden@weizmann.ac.il